share_log

OneMedNet Files Amendment to Form S-4 in Connection With Its Proposed Business Combination With Data Knights Acquisition Corp.

OneMedNet Files Amendment to Form S-4 in Connection With Its Proposed Business Combination With Data Knights Acquisition Corp.

OneMedNet檔案修正案,以形成S-4,與其與Data Knight Acquisition Corp.擬議的業務合併相關。
Accesswire ·  2023/01/05 02:36

~ Amended Filing Represents Progress Towards Merger Completion ~

~修改後的申請代表着完成合並的進展~

~ Merger Expected to Close in the First Quarter of 2023 ~

~合併預計將於2023年第一季度完成~

MINNEAPOLIS, MN and LONDON, UK / ACCESSWIRE / January 4, 2023 // OneMedNet Corporation, an experienced curator of regulatory-grade Imaging Real Word Data ("RWD") has continued the process to become a publicly-listed company through a merger with Data Knights Acquisition Corp. ("Data Knights") (Nasdaq:DKDCA, DKDCW), a special purpose acquisition company, when Data Knights submitted its second amendment to its Form S-4 (the "Registration Statement") with the Securities and Exchange Commission.

明尼蘇達州明尼阿波利斯和英國倫敦/ACCESSWIRE/2023年1月4日//OneMedNet Corporation是一家經驗豐富的監管級別成像真實數據(RWD)管理人,在Data Knights向美國證券交易委員會提交其S-4表格(“註冊聲明”)的第二次修訂時,該公司通過與特殊目的收購公司Data Knight Acquisition Corp.(以下稱“Data Knights”)(納斯達克代碼:DKDCA,DKDCW)合併,成為一家上市公司。

OneMedNet and Data Knights announced their definitive merger agreement on April 25, 2022. Upon closing of the transaction, which is anticipated to occur in the first quarter of 2023, OneMedNet will become a publicly listed company and is expected to trade on the Nasdaq Global Select under the symbol "ONMD."

OneMedNet和Data Knight於2022年4月25日宣佈了最終的合併協議。這筆交易預計將於2023年第一季度完成,交易完成後,OneMedNet將成為一家上市公司,預計將在納斯達克全球精選市場以“ONMD”的代碼進行交易。

In support of closing the merger, as previously announced, on November 11, 2022, Data Knights held a virtual special meeting. At the special meeting the stockholders approved the Extension Amendment Proposal, giving Data Knights the right to extend the date from November 11, 2022 by up to nine (9) one-month extensions to August 11, 2023. Additionally, at the special meeting the stockholders approved the amendment to Data Knights' Investment Management Trust Agreement to extend the date on which Continental Stock Trust & Transfer must liquidate the Trust Account established in connection with Data Knights' IPO if Data Knights has not completed its initial business combination, from November 11, 2022 to August 11, 2023.

為了支持完成合並,正如之前宣佈的那樣,2022年11月11日,數據騎士召開了一次虛擬的特別會議。在特別會議上,股東們批准了延期修正案提案,賦予數據騎士公司將日期從2022年11月11日延長最多九(9)個月至2023年8月11日的權利。此外,股東在特別會議上批准了數據騎士投資管理信託協議的修正案,將如果數據騎士尚未完成其初始業務合併,大陸股票信託和轉移公司必須清算與數據騎士首次公開募股有關的信託賬户的日期從2022年11月11日延長至2023年8月11日。

The Registration Statement contains a preliminary proxy statement and prospectus, in connection with OneMedNet's previously announced proposed business combination with Data Knights. While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about OneMedNet and the proposed business combination with Data Knights.

註冊聲明包含一份初步的委託書和招股説明書,與OneMedNet之前宣佈的與數據騎士的擬議業務合併有關。雖然註冊聲明尚未生效,其中包含的信息可能會更改,但它提供了有關OneMedNet和擬議與Data Knight的業務合併的重要信息。

Additional Information and Where to Find it

其他信息以及在哪裏可以找到它

This press release relates to a proposed transaction between Data Knights and OneMedNet. In connection with the proposed transaction, Data Knights filed a Registration Statement on Form S-4 with the SEC, which is subject to change, and which includes a proxy statement of Data Knights in connection with Data Knight's solicitation of proxies for vote by Data Knight's shareholders with respect to the proposed transaction and a prospectus of Data Knights relating to the issuance of Data Knights' securities to the stockholders of OneMedNet. Data Knights may also file other documents regarding the proposed transaction with the SEC.

本新聞稿涉及Data Knight和OneMedNet之間擬議的交易。關於擬議的交易,數據騎士向美國證券交易委員會提交了一份S-4表格的註冊説明書,其中包括一份與數據騎士就擬議的交易徵求委託書供數據騎士的股東投票相關的數據騎士的委託書,以及一份與向OneMedNet的股東發行數據騎士的證券有關的數據騎士的招股説明書。數據騎士還可以向美國證券交易委員會提交有關擬議交易的其他文件。

This communication does not contain all the information that should be considered concerning the proposed transaction and is not intended to form the basis of any investment decision or any other decision in respect of the proposed transaction. Before making any voting or investment decision, investors and security holders are urged to read the registration statement and the proxy statement/prospectus, each which have not yet become effective and the information contained therein is subject to change, together with all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

本函件並不包含與擬議交易有關的應考慮的所有信息,也無意成為關於擬議交易的任何投資決定或任何其他決定的基礎。在做出任何投票或投資決定之前,投資者和證券持有人應閲讀尚未生效的登記聲明和委託書/招股説明書,以及所有其他已提交或將提交給美國證券交易委員會的與擬議交易相關的文件,因為它們將包含有關擬議交易的重要信息。

Investors and security holders are able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Data Knights through the website maintained by the SEC at www.sec.gov.

投資者和證券持有人可以通過美國證券交易委員會維護的網站免費獲取美國證券交易委員會已提交或將提交美國證券交易委員會的登記聲明、委託書/招股説明書和所有其他相關文件的副本。

Investors and security holders will be able to obtain free copies of the registration statement proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Circle and Concord through the website maintained by the SEC at www.sec.gov or by directing a request to: Trident Court, 1 Oakcroft Road, Chessington, Surrey KT9 1BD, United Kingdom.

投資者和證券持有人將能夠免費獲得註冊聲明、委託書/招股説明書以及環宇和協和向美國證券交易委員會提交或將提交給美國證券交易委員會的所有其他相關文件的副本,這些文件可以通過美國證券交易委員會維護的網站www.sec.gov或通過向以下地址提出請求:英國薩裏郡切辛頓市奧剋剋羅夫特路1號三叉戟法院。

NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THIS PRESS RELEASE, PASSED UPON THE MERITS OR FAIRNESS OF THE BUSINESS COMBINATION OR RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS PRESS RELEASE. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

美國證券交易委員會和任何州證券監督管理機構都沒有批准或不批准本新聞稿中描述的交易,沒有傳遞業務合併或關聯交易的優點或公平性,也沒有傳遞本新聞稿中披露的充分性或準確性。任何相反的陳述都構成刑事犯罪。

About OneMedNet Corporation

關於OneMedNet公司

Founded in 2009, OneMedNet unlocks the significant value contained within the clinical image archives of healthcare providers by transforming Real-World Data into a valuable, quality asset that can help clinicians improve care and lower costs. Employing its proven OneMedNet iRWD solution, OneMedNet securely de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network, together with industry leading technology and in-house clinical expertise, OneMedNet successfully meets the most rigorous Real-World Data Life Science requirements. OneMedNet is led by its Chief Executive Officer, Paul Casey and Chief Medical Officer, Dr. Jeffrey Yu.

OneMedNet成立於2009年,通過將真實世界數據轉換為可幫助臨牀醫生改善護理和降低成本的有價值的優質資產,釋放了醫療保健提供商的臨牀圖像檔案中包含的重大價值。利用其成熟的OneMedNet iRWD解決方案,OneMedNet安全地識別、搜索和管理本地數據檔案,為提供商帶來豐富的內部和第三方研究機會。通過利用這種廣泛的聯合提供商網絡、行業領先的技術和內部臨牀專業知識,OneMedNet成功地滿足了最嚴格的真實世界數據生命科學要求。OneMedNet由其首席執行官保羅·凱西和首席醫療官傑弗裏·餘博士領導。

About Data Knights Acquisition Corp.

關於數據騎士收購公司

Data Knights Acquisition Corp. is a blank check company formed for the purposes of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more tech or software businesses or entities. Data Knights is led by its Chief Executive Officer, Barry Anderson, and its Founder and Chief Financial Officer, Firdauz Edmin Bin Mokhtar.

數據騎士收購公司是一家空白支票公司,成立的目的是與一個或多個技術或軟件業務或實體進行合併、資本股票交換、資產收購、股票購買、重組或類似的業務合併。數據騎士由其首席執行官巴里·安德森和創始人兼首席財務官Firdauz Edmin Bin Mokhtar領導。

Participants in the Solicitation

徵集活動的參與者

OneMedNet, Data Knights and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from Data Knights' shareholders in connection with the proposed transaction. A list of the names of such persons and information regarding their interests in the proposed business combination are contained in the definitive proxy statement/prospectus. You may obtain free copies of these documents free of charge by directing a written request to Data Knights or OneMedNet. You can find more information about Data Knights' directors and executive officers in Data Knights' final prospectus dated May 6, 2021, and filed with the SEC on May 10, 2021. The definitive proxy statement will be transmitted to Data Knights' shareholders as of a record date to be established for voting on the proposed business combination when it becomes available. Shareholders, potential investors, and other interested persons should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above.

根據美國證券交易委員會規則,OneMedNet、數據騎士及其各自的若干董事、高管和其他管理層成員及員工可被視為參與就擬議交易向數據騎士股東徵集委託書的活動。最終委託書/招股説明書中載有該等人士的姓名及其在擬議業務合併中的權益的信息。您可以通過向Data Knight或OneMedNet發出書面請求來免費獲取這些文檔的副本。你可以在數據騎士於2021年5月6日提交給美國證券交易委員會的最終招股説明書中找到更多關於數據騎士董事和高管的信息。最終的委託書將在創紀錄的日期發送給數據騎士的股東,以便在擬議的業務合併可用時進行投票。股東、潛在投資者和其他有利害關係的人在作出任何投票或投資決定之前,應仔細閲讀委託書/招股説明書。您可以從上述來源獲得這些文檔的免費副本。

Non-Solicitation

非邀請性

This press release relates to a proposed business combination between OneMedNet and Data Knights Acquisition Corp and is not intended and does not constitute a proxy statement or solicitation of a proxy and does not constitute an offer to sell or a solicitation of an offer to buy the securities of Data Knights Acquisition Corp. or OneMedNet, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be deemed to be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom.

本新聞稿涉及OneMedNet和Data Knights Acquisition Corp之間擬議的業務合併,不打算也不構成代理聲明或委託邀請,也不構成出售或邀請購買Data Knight Acquisition Corp.或OneMedNet的證券的要約,也不會在任何州或司法管轄區出售任何此類證券,在該州或司法管轄區的證券註冊或資格登記或資格之前,此類出售將是非法的。除非通過符合證券法第10節要求的招股説明書或豁免招股説明書,否則不得被視為提出證券要約。

Cautionary Statement Regarding Forward-Looking Statements

關於前瞻性陳述的警告性聲明

Certain statements contained in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements may include, but are not limited to, statements with respect to (i) trends in the real world medical data industry, including changes in U.S. and state laws, regulations and guidance related to OneMedNet's products and services; (ii) OneMedNet's growth prospects and OneMedNet's market size; (iii) OneMedNet projected financial and operational performance including relative to its competitors; (iv) new product and service offerings OneMedNet may introduce in the future; (v) the potential transaction, including the implied enterprise value, the expected post-closing ownership structure and the likelihood and ability of the parties to consummate the potential transaction successfully; (vi) the risk the proposed business combination may not be completed in a timely manner or at all, which may adversely affect the price of Data Knights' securities; (vii) the failure to satisfy the conditions to the consummation of the proposed business combination, including the approval of the proposed business combination by the stockholders of Data Knights Acquisition Corp.; (viii) the effect of the announcement or pendency of the proposed business combination on Data Knights' or OneMedNet's business relationships, performance and business generally; (ix) the outcome of any legal proceedings that be instituted against Data Knights or OneMedNet related to the proposed business combination or any agreement related thereto; (x) the ability to maintain the listing of Data Knights on Nasdaq; (xi) the price of Data Knights' securities, including volatility resulting from changes in the competitive and regulated industry in which OneMedNet operates, variations in performance across competitors, changes in laws and regulations affecting OneMedNet's business and changes in the combined capital structure; (xii) the ability to implement business pans, forecasts, and other expectations after the completion of the proposed business combination and identify and realize additional opportunities; and (xiii) other statements regarding Data Knights' or OneMedNet's expectations, hopes, beliefs, intentions and strategies regarding the future.

本新聞稿中包含的某些陳述構成聯邦證券法所指的“前瞻性陳述”。前瞻性陳述可能包括但不限於:(I)真實世界醫療數據行業的趨勢,包括與OneMedNet的產品和服務相關的美國和州法律、法規和指導方針的變化;(Ii)OneMedNet的增長前景和OneMedNet的市場規模;(Iii)OneMedNet的預期財務和運營業績,包括相對於其競爭對手;(Iv)OneMedNet未來可能推出的新產品和服務;(V)潛在交易,包括隱含的企業價值、交易完成後的預期所有權結構以及各方成功完成潛在交易的可能性和能力;(Vi)擬議的業務合併可能無法及時完成或根本無法完成的風險,這可能對Data Knight的證券價格產生不利影響;(Vii)未能滿足完成擬議的業務合併的條件,包括Data Knight Acquisition Corp.的股東批准擬議的業務合併;(Viii)建議的業務合併的宣佈或懸而未決對數據騎士或OneMedNet的業務關係、業績和一般業務的影響;(Ix)與建議的業務合併或與之相關的任何協議對數據騎士或OneMedNet提起的任何法律訴訟的結果;(X)維持數據騎士在納斯達克上上市的能力;(Xi)數據騎士的證券價格,包括因OneMedNet運營的競爭和受監管的行業發生變化而導致的波動,以及競爭對手之間的業績差異, (Ii)有關數據騎士或OneMedNet對未來的期望、希望、信念、意圖及策略的其他陳述;(Vii)影響OneMedNet業務的法律法規的變化及合併資本結構的變化;(Xii)在建議的業務合併完成後實施業務PAN、預測及其他預期的能力,以及識別及實現額外機會的能力。

In addition, any statements that refer to projections forecasts or other characterizations of future events or circumstances, including any underlying assumptions are forward-looking statements. he words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "outlook," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject, are subject to risks and uncertainties.

此外,任何提及未來事件或情況的預測、預測或其他特徵,包括任何基本假設的陳述均為前瞻性陳述。“預期”、“相信”、“繼續”、“可能”、“估計”、“預期”、“打算”、“展望”、“可能”、“可能”、“計劃”、“可能”、“潛在”、“預測”、“項目”、“應該”、“將會”以及類似的表述可以識別前瞻性陳述,但沒有這些詞語並不意味着陳述不具有前瞻性。前瞻性陳述是基於當前預期和假設對未來事件的預測、預測和其他陳述,因此會受到風險和不確定因素的影響。

You should carefully consider the risks and uncertainties described in the "Risk Factors" section of Data Knights Acquisition Corp.'s registration statement on Form S-1, any proxy statement relating to the transaction filed by Data Knights Acquisition Corp with the SEC, other documents filed by Data Knights Acquisition Corp from time to time with SEC, and any risk factors made available to you in connection with Data Knights Acquisition Corp., OneMedNet, and the transaction. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond the control of OneMedNet and Data Knights Acquisition Corp.) and other assumptions, that may cause the actual results or performance to be materially different from those expressed or implied by these forward-looking statements.

閣下應仔細考慮Data Knights Acquisition Corp.提交的S-1表格註冊聲明中“風險因素”一節中描述的風險和不確定因素,Data Knights Acquisition Corp.向美國證券交易委員會提交的與交易有關的任何委託書,數據騎士收購公司不時向美國證券交易委員會提交的其他文件,以及向您提供的與Data Knight Acquisition Corp.、OneMedNet和這筆交易相關的任何風險因素。這些前瞻性聲明涉及許多風險和不確定性(其中一些風險和不確定性不在OneMedNet和Data Knight Acquisition Corp.的控制範圍之內)。以及其他假設,可能會導致實際結果或業績與這些前瞻性陳述明示或暗示的結果或表現大不相同。

Contacts

聯繫人

Investor Contact
Shannon Devine
MZ Group North America
203-741-8811
OMN@mzgroup.us

投資者聯繫方式
香農·迪瓦恩
MZ集團北美
203-741-8811
郵箱:omn@mzgroup.us

SOURCE: ONEMEDNET CORP.

資料來源:ONEMEDNET公司


View source version on accesswire.com:
在accesswire.com上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論